North Carolina State University has synthesized vancomycin derivatives containing a 2,3-pyrrolidinedione moiety and reported to be useful for the treatment of bacterial infections.

Gilead Sciences Inc. has disclosed bridged tricyclic carbamoylpyridone compounds reported to be useful for the treatment of HIV infection.

Corbus Pharmaceuticals Holding Inc. has described cannabinoid CB1 receptor antagonists or inverse agonists reported to be useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases.

Crossignal Therapeutics Inc. has divulged G-protein coupled receptor GPR35 antagonists reported to be useful for the treatment of cancer.

Alesta Therapeutics BV has identified eukaryotic translation initiation factor 2-α kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer.

Uniquest Pty Ltd. has synthesized tyrosine-protein kinase SYK inhibitors reported to be useful for the treatment of allergy, cancer, fungal infections, rheumatoid arthritis, osteoporosis, liver, lung and periodontal diseases, among others.

Brenig Therapeutics Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others.

Rapt Therapeutics Inc. has described chemokine CCR4 receptor antagonists reported to be useful for the treatment of cancer, allergic asthma, contact dermatitis, allergic rhinitis, immunological, inflammatory, cardiovascular and metabolic disorders.

The Commissariat à l'énergie atomique (CEA) has divulged dihydroquinazolinone compounds reported to be useful for the treatment of viral infections.

Vertex Pharmaceuticals Inc. has identified cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.